CIB0.DE vs. ETLI.DE
Compare and contrast key facts about VanEck Bionic Engineering UCITS ETF A (CIB0.DE) and L&G Pharma Breakthrough UCITS ETF (ETLI.DE).
CIB0.DE and ETLI.DE are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. CIB0.DE is a passively managed fund by VanEck that tracks the performance of the MVIS Global Bionic Healthcare ESG. It was launched on Dec 2, 2022. ETLI.DE is a passively managed fund by Legal & General that tracks the performance of the Solactive Pharma Breakthrough Value. It was launched on Jan 18, 2018. Both CIB0.DE and ETLI.DE are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Performance
CIB0.DE vs. ETLI.DE - Performance Comparison
Loading graphics...
CIB0.DE vs. ETLI.DE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
CIB0.DE VanEck Bionic Engineering UCITS ETF A | -9.78% | -10.00% | 5.16% | 2.09% | -1.65% |
ETLI.DE L&G Pharma Breakthrough UCITS ETF | 1.80% | 22.23% | 0.42% | -12.64% | -1.25% |
Returns By Period
In the year-to-date period, CIB0.DE achieves a -9.78% return, which is significantly lower than ETLI.DE's 1.80% return.
CIB0.DE
- 1D
- 1.37%
- 1M
- -8.85%
- YTD
- -9.78%
- 6M
- -3.29%
- 1Y
- -11.01%
- 3Y*
- -6.52%
- 5Y*
- —
- 10Y*
- —
ETLI.DE
- 1D
- 2.16%
- 1M
- 2.73%
- YTD
- 1.80%
- 6M
- 7.95%
- 1Y
- 22.40%
- 3Y*
- 4.82%
- 5Y*
- 2.36%
- 10Y*
- —
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
CIB0.DE vs. ETLI.DE - Expense Ratio Comparison
CIB0.DE has a 0.55% expense ratio, which is higher than ETLI.DE's 0.49% expense ratio.
Return for Risk
CIB0.DE vs. ETLI.DE — Risk / Return Rank
CIB0.DE
ETLI.DE
CIB0.DE vs. ETLI.DE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for VanEck Bionic Engineering UCITS ETF A (CIB0.DE) and L&G Pharma Breakthrough UCITS ETF (ETLI.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CIB0.DE | ETLI.DE | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.56 | 1.07 | -1.63 |
Sortino ratioReturn per unit of downside risk | -0.68 | 1.51 | -2.19 |
Omega ratioGain probability vs. loss probability | 0.92 | 1.20 | -0.28 |
Calmar ratioReturn relative to maximum drawdown | -0.70 | 2.01 | -2.71 |
Martin ratioReturn relative to average drawdown | -1.80 | 7.18 | -8.98 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| CIB0.DE | ETLI.DE | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.56 | 1.07 | -1.63 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 0.14 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.25 | 0.25 | -0.50 |
Correlation
The correlation between CIB0.DE and ETLI.DE is 0.47, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Dividends
CIB0.DE vs. ETLI.DE - Dividend Comparison
Neither CIB0.DE nor ETLI.DE has paid dividends to shareholders.
Drawdowns
CIB0.DE vs. ETLI.DE - Drawdown Comparison
The maximum CIB0.DE drawdown since its inception was -26.12%, smaller than the maximum ETLI.DE drawdown of -30.83%. Use the drawdown chart below to compare losses from any high point for CIB0.DE and ETLI.DE.
Loading graphics...
Drawdown Indicators
| CIB0.DE | ETLI.DE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -26.12% | -30.83% | +4.71% |
Max Drawdown (1Y)Largest decline over 1 year | -15.52% | -14.80% | -0.72% |
Max Drawdown (5Y)Largest decline over 5 years | — | -30.83% | — |
Current DrawdownCurrent decline from peak | -24.58% | -1.36% | -23.22% |
Average DrawdownAverage peak-to-trough decline | -9.86% | -10.38% | +0.52% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.06% | 3.40% | +2.66% |
Volatility
CIB0.DE vs. ETLI.DE - Volatility Comparison
The current volatility for VanEck Bionic Engineering UCITS ETF A (CIB0.DE) is 5.01%, while L&G Pharma Breakthrough UCITS ETF (ETLI.DE) has a volatility of 7.39%. This indicates that CIB0.DE experiences smaller price fluctuations and is considered to be less risky than ETLI.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| CIB0.DE | ETLI.DE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.01% | 7.39% | -2.38% |
Volatility (6M)Calculated over the trailing 6-month period | 12.42% | 14.09% | -1.67% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.46% | 20.90% | -1.44% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 17.80% | 17.01% | +0.79% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 17.80% | 18.87% | -1.07% |